Regeneron genetics center discovers rare mutations in the cideb gene that protect against liver disease

New research published in the new england journal of medicine reveals that people with certain genetic loss-of-function mutations have more than 50% lower risk of nonalcoholic liver disease and nonalcoholic cirrhosis regeneron and alnylam have developed an sirna therapeutic candidate targeting cideb that could enter clinical stages of development in the next year unprecedented size of regeneron genetics center human sequence database – representing approximately two million individuals and growing – enables discovery of protective gene variants too rare to be previously identified tarrytown, n.y. , july 27, 2022 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) announced today that scientists from the regeneron genetics center® (rgc) have uncovered rare genetic loss-of-function mutations in the cideb gene that are associated with substantial protection from liver disease, including serious diseases such as nonalcoholic steatohepatitis (nash) and cirrhosis.
REGN Ratings Summary
REGN Quant Ranking